"Recombinant humanized collagen type III with high antitumor activity inhibits breast cancer cells autophagy, proliferation, and migration through DDR1"

作者全名："Liu, Xiaowei; Li, Hu; Wang, Tingrui; Yang, Ting; Yang, Xia; Guo, Kaixuan; Hu, Lina; Ming, Jia"

作者地址："[Liu, Xiaowei; Wang, Tingrui; Yang, Ting; Ming, Jia] Chongqing Med Univ, Affiliated Hosp 2, Dept Breast & Thyroid Surg, Chongqing 400010, Peoples R China; [Li, Hu; Hu, Lina] Chongqing Med Univ, Affiliated Hosp 2, Dept Obstet & Gynecol, Chongqing 400010, Peoples R China; [Hu, Lina] Minist Educ, Joint Int Res Lab Reprod & Dev, Chongqing 400010, Peoples R China; [Hu, Lina] Reprod & Stem Cell Therapy Res Ctr Chongqing, Chongqing 400010, Peoples R China; [Yang, Xia; Guo, Kaixuan] Shanxi Jinbo Biopharmaceut Co Ltd, Shanxi Key Lab Funct Prot, Taiyuan 030032, Shanxi, Peoples R China"

通信作者："Ming, J (通讯作者)，Chongqing Med Univ, Affiliated Hosp 2, Dept Breast & Thyroid Surg, Chongqing 400010, Peoples R China.; Hu, LA (通讯作者)，Chongqing Med Univ, Affiliated Hosp 2, Dept Obstet & Gynecol, Chongqing 400010, Peoples R China.; Hu, LA (通讯作者)，Minist Educ, Joint Int Res Lab Reprod & Dev, Chongqing 400010, Peoples R China.; Hu, LA (通讯作者)，Reprod & Stem Cell Therapy Res Ctr Chongqing, Chongqing 400010, Peoples R China."

来源：INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES

ESI学科分类：BIOLOGY & BIOCHEMISTRY

WOS号：WOS:001023545200001

JCR分区：Q1

影响因子：7.7

年份：2023

卷号：243

期号：　

开始页：　

结束页：　

文献类型：Article

关键词：Recombinant humanized collagen type III; DRR1; Autophagy; Breast cancer

摘要："Breast cancer (BC) has become the most common cancer in the world and lacks safe and efficient treatment. The novel biomaterial recombinant humanized collagen type III (rhCOLIII) has been reported to have various biological functions, such as promoting skin extracellular matrix regeneration and improving the cell microenvironment, but its role in breast cancer is unclear. In this study, we first found that rhCOLIII inhibited the proliferation, migration, and invasion of breast cancer cells (BCCs) but had no effect on the survival of normal breast epithelial cells. In addition, rhCOLIII not only promoted apoptosis and dormancy of BCCs but also inhibited autophagy within BCCs. Subsequently, RNA-Seq analysis suggested that DDR1 may be a key target for rhCOLIII to exert antitumor effects, and we validated that inhibition of DDR1 eliminated the effects of rhCOLIII on the proliferation, migration, apoptosis, dormancy and autophagy of BCCs. Moreover, rhCOLIII treatment was found to reduce the tumorigenic activity of BCCs in animal experiments and to upregulate DDR1 protein expression while inhibiting autophagy at the tissue level. Therefore, rhCOLIII may serve as a potential treatment method for BC patients and is expected to improve the prognosis of patients."

基金机构：Kuanren meritocrat ' Backbone Talents Project of The Second Affiliated Hospital of Chongqing Medical University [KY2019G0160]; Wu Jieping Medical Foundation [320.6750.2021-10-86]

基金资助正文："This work was supported by the Kuanren meritocrat ' Backbone Talents Project of The Second Affiliated Hospital of Chongqing Medical University (No. KY2019G0160) and Wu Jieping Medical Foundation ' (No. 320.6750.2021-10-86) . We gratefully acknowledge Shanxi Jinbo BioPharmaceutical Co., Ltd. for their help in providing rhCOLIII."